SIMCERE PHARMA (02096) jumped more than 5% in early trading on Wednesday, with shares last up 4.27% at HK$12.69, recording a turnover of HK$40.17 million. The stock's upward momentum comes as investors position ahead of the company's 2026 interim results presentation scheduled for August 21.

According to the company's positive profit alert, first-half revenue is projected to reach RMB 4.55 billion to RMB 4.61 billion, representing year-on-year growth of approximately 26.9% to 28.6%. Net profit attributable to shareholders is expected to land between RMB 810 million and RMB 860 million, up roughly 34.8% to 43.1% from the prior year period. Adjusted net profit attributable to shareholders is forecast at RMB 950 million to RMB 1 billion, marking a year-on-year increase of approximately 46.5% to 54.2%. The robust performance is primarily attributed to higher revenue from innovative drugs and out-licensing income.

Huatai Securities noted that despite industry volatility in the second quarter, the company delivered results exceeding market expectations, reflecting strong market demand for its new product pipeline and efficiency gains following management changes. The brokerage added that the normalization of business development activities is expected to generate sustained incremental contributions. Huatai projects the company's full-year organic business will maintain the momentum indicated in its interim profit alert, while profit growth is set to accelerate further supported by business development income. The firm maintains a "Buy" rating on the stock.